Targeting the PI3K/Akt/mTOR-pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.Ippen FM, Grosch JK, Subramanian M, Kuter BM, Liederer BM, Plise EG, Mora JL, Nayyar N, Schmidt SP, Giobbie-Hurder A, Martinez-Lage M, Carter SL, Cahill DP, Wakimoto H, Brastianos PK.Neuro Oncol. 2019 Jun 7. pii: noz105. doi: 10.1093/neuonc/noz105.

Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?Tom MC, Cahill DP, Buckner JC, Dietrich J, Parsons MW, Yu JS.Am Soc Clin Oncol Educ Book. 2019 Jan;39:133-145. doi: 10.1200/EDBK_238353. Epub 2019 May 17.

TERT Alterations in Progressive Treatment-Resistant Meningiomas.Juratli TA, Brastianos PK, Cahill DP.Neurosurgery. 2018 Sep 1;65(CN_suppl_1):66-68. doi: 10.1093/neuros/nyy154.

PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma.Tanaka S, Batchelor TT, Iafrate AJ, Dias-Santagata D, Borger DR, Ellisen LW, Yang D, Louis DN, Cahill DP, Chi AS.Acta Neuropathol Commun. 2019 Apr 29;7(1):66. doi: 10.1186/s40478-019-0720-8.

PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors.Tateishi K, Nakamura T, Juratli TA, Williams EA, Matsushita Y, Miyake S, Nishi M, Miller JJ, Tummala SS, Fink AL, Lelic N, Koerner MVA, Miyake Y, Sasame J, Fujimoto K, Tanaka T, Minamimoto R, Matsunaga S, Mukaihara S, Shuto T, Taguchi H, Udaka N, Murata H, Ryo A, Yamanaka S, Curry WT, Dias-Santagata D, Yamamoto T, Ichimura K, Batchelor TT, Chi AS, Iafrate AJ, Wakimoto H, Cahill DP.Clin Cancer Res. 2019 Apr 11. doi: 10.1158/1078-0432.CCR-18-4144.

Factors that modify the risk of intraoperative seizures triggered by electrical stimulation during supratentorial functional mapping.Dineen J, Maus DC, Muzyka I, See RB, Cahill DP, Carter BS, Curry WT, Jones PS, Nahed BV, Peterfreund RA, Simon MV. Clin Neurophysiol. 2019 Jun;130(6):1058-1065. doi: 10.1016/j.clinph.2019.03.006. Epub 2019 Mar 23.

Receptor tyrosine kinase gene amplification is predictive of intraoperative seizures during glioma resection with functional mapping.Choi BD, Lee DK, Yang JC, Ayinon CM, Lee CK, Maus D, Carter BS, Barker FG, Jones PS, Nahed BV, Cahill DP, See RB, Simon MV, Curry WT. J Neurosurg. 2019 Mar 29:1-7. doi: 10.3171/2018.12.JNS182700.

Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control.Alvarez-Breckenridge C, Giobbie-Hurder A, Gill CM, Bertalan M, Stocking J, Kaplan A, Nayyar N, Lawrence DP, Flaherty KT, Shih HA, Oh K, Batchelor TT, Cahill DP, Sullivan R, Brastianos PK. Oncologist. 2019 May;24(5):671-679. doi: 10.1634/theoncologist.2018-0306. Epub 2019 Feb 22.

The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases.Ippen FM, Alvarez-Breckenridge CA, Kuter BM, Fink AL, Bihun IV, Lastrapes M, Penson T, Schmidt SP, Wojtkiewicz GR, Ning J, Subramanian M, Giobbie-Hurder A, Martinez-Lage M, Carter SL, Cahill DP, Wakimoto H, Brastianos PK. Clin Cancer Res. 2019 Jun 1;25(11):3374-3383. doi: 10.1158/1078-0432.CCR-18-3049. Epub 2019 Feb 22.

MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. Nayyar N, White MD, Gill CM, Lastrapes M, Bertalan M, Kaplan A, D’Andrea MR, Bihun I, Kaneb A, Dietrich J, Ferry JA, Martinez-Lage M, Giobbie-Hurder A, Borger DR, Rodriguez FJ, Frosch MP, Batchelor E, Hoang K, Kuter B, Fortin S, Holdhoff M, Cahill DP, Carter S, Brastianos PK, Batchelor TT. Blood Adv. 2019 Feb 12;3(3):375-383. doi: 10.1182/bloodadvances.2018027672.

Performance of a Hospital Pathway for Patients With a New Single Brain Mass. Arrillaga-Romany I, Curry WT Jr, Jordan JT, Cahill DP, Nahed BV, Martuza RL, Loeffler JS, Järhult SJ, Muzikansky A, Cohen AB, Singhal AB, Goldstein JN, Batchelor TT. J Oncol Pract. 2019 Mar;15(3):e211-e218. doi: 10.1200/JOP.17.00098. Epub 2019 Jan 25.

Accelerated progression of IDH mutant glioma after first recurrence. Miller JJ, Loebel F, Juratli TA, Tummala SS, Williams EA, Batchelor TT, Arrillaga-Romany I, Cahill DP. Neuro Oncol. 2019 May 6;21(5):669-677. doi: 10.1093/neuonc/noz016.

Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy. Tanaka S, Luk S, Kiyokawa J, Onozato ML, Iafrate AJ, Shah K, Martuza RL, Rabkin SD, Batchelor TT, Cahill DP, Chi AS, Wakimoto H. Sci Rep. 2019 Jan 15;9(1):139. doi: 10.1038/s41598-018-37437-2

Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups. Juratli TA, Tummala SS, Riedl A, Daubner D, Hennig S, Penson T, Zolal A, Thiede C, Schackert G, Krex D, Miller JJ, Cahill DP. J Neurooncol. 2019 Jan;141(2):327-335. doi: 10.1007/s11060-018-03034-6. Epub 2018 Dec 7.

Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. Bale TA, Jordan JT, Rapalino O, Ramamurthy N, Jessop N, DeWitt JC, Nardi V, Alvarez MM, Frosch M, Batchelor TT, Louis DN, Iafrate AJ, Cahill DP, Lennerz JK. Neuro Oncol. 2019 May 6;21(5):596-605. doi: 10.1093/neuonc/noy201.

A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas. Fujio S, Juratli TA, Arita K, Hirano H, Nagano Y, Takajo T, Yoshimoto K, Bihun IV, Kaplan AB, Nayyar N, Fink AL, Bertalan MS, Tummala SS, Curry WT Jr, Jones PS, Martinez-Lage M, Cahill DP, Barker FG 2nd, Brastianos PK. Neurosurgery. 2018 Nov 27. doi: 10.1093/neuros/nyy569.

Extent of Resection Versus Molecular Classification: What Matters When? Clark VE, Cahill DP. Neurosurg Clin N Am. 2019 Jan;30(1):95-101. doi: 10.1016/j.nec.2018.08.006. Review.

Updates in prognostic markers for gliomas. Aquilanti E, Miller J, Santagata S, Cahill DP, Brastianos PK. Neuro Oncol. 2018 Nov 9;20(suppl_7):vii17-vii26. doi: 10.1093/neuonc/noy158.

Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma. Spino M, Kurz SC, Chiriboga L, Serrano J, Zeck B, Sen N, Patel S, Shen G, Vasudevaraja V, Tsirigos A, Suryadevara CM, Frenster JD, Tateishi K, Wakimoto H, Jain R, Riina HA, Nicolaides TP, Sulman EP, Cahill DP, Golfinos JG, Isse K, Saunders LR, Zagzag D, Placantonakis DG, Snuderl M, Chi AS. Clin Cancer Res. 2019 Feb 15;25(4):1261-1271. doi: 10.1158/1078-0432.CCR-18-2312. Epub 2018 Nov 5.

TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations. Williams EA, Miller JJ, Tummala SS, Penson T, Iafrate AJ, Juratli TA, Cahill DP. Acta Neuropathol Commun. 2018 Oct 17;6(1):106. doi: 10.1186/s40478-018-0613-2.

Close Menu